Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

Bristol-Myers Gets FDA Nod for Label Expansion of Opdivo

Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma.

Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study

Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck (MRK) closed the most recent trading day at $81.77, moving -0.6% from the previous trading session.

Merck's Keytruda Fails in First-Line Bladder Cancer Study

Merck's (MRK) phase III advanced bladder cancer study on Keytruda fails to meet dual primary endpoints of overall survival (OS) or progression-free survival (PFS).

Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication

The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.

Bayer (BAYRY) Submits Applications for Heart Failure Drug

Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.

AstraZeneca to Ensure Equal Access to Coronavirus Vaccine

AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M

The Zacks Analyst Blog Highlights: Alibaba, UnitedHealth, Merck, PetroChina and 3M

Kinjel Shah headshot

Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report

The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.

AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer

AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.

Roche Tecentriq-Avastin Combo Gets FDA Nod for Liver Cancer

FDA approves Roche's (RHHBY) sBLA seeking approval of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

Sheraz Mian headshot

Top Stock Reports for Alibaba, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), UnitedHealth (UNH) and Merck (MRK).

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Benjamin Rains headshot

3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

Sweta Killa headshot

Best-Performing ETFs of Last Week

While the rally was broad-based, airline and banking industry led the way higher last week.

Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers

The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers

Tirthankar Chakraborty headshot

5 Top Stocks Up 100%+ in May With More Room to Run

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Daniel Laboe headshot

Merck (MRK) Shares Looking Ripe For A Buy

Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis

FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid

With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.

Daniel Laboe headshot

Buy Merck Stock On Vaccine Hopes

Analysts are estimating the vaccine could boost Merck's topline by anywhere between $2 to $5 billion

Kinjel Shah headshot

Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN

Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.

Why Is Merck (MRK) Down 4% Since Last Earnings Report?

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.